Join Now

Project Details
  • Title: A novel pan PI3-kinase inhibitor (SF1126) in the treatment of medulloblastoma
  • Date Proposed: 04/20/2008
  • Amount Requested: $20,000.00
  • Amount we Paid: $20,000.00
  • Paid Date: 05/15/2008
  • Stauts: Funded - and in progress!
  • Research name: Carrie R. Muh, MD
  • Hospital: Emory University School of Medicine
  • Grey Ribbon Crusade Participants:
    • Musella Foundation For Brain Tumor Research & Information, Inc
    • Unlocking Brain Tumors, Inc
  • Simple Description: Medulloblastoma is the most common brain tumor of childhood and prognosis is poor, with only half of patients surviving five years after diagnosis. Recently, much of the molecular pathway involved in medulloblastoma has been elucidated and PI3-kinases (PI3K) have been shown to play a significant role. Our laboratory recently described the development of a novel pan PI3-kinase inhibitor, SF1126. We intend to study SF1126 in murine medulloblastoma models and believe that this compound will have anti-tumor and anti-angiogenic effects. Despite the importance of PI3-kinase in tumorigenesis, inhibitors of this pathway are lacking in clinical studies. This project should provide important information regarding the use of this drug in medulloblastoma treatment, and may ultimately benefit human patients through the development of a new therapeutic agent. The eventual goal will be to prepare this compound for a phase I clinical trial in human patients with medulloblastoma.